Compare AIN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | HRMY |
|---|---|---|
| Founded | 1895 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1994 | 2020 |
| Metric | AIN | HRMY |
|---|---|---|
| Price | $59.81 | $31.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $60.25 | $44.11 |
| AVG Volume (30 Days) | 199.3K | ★ 890.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | 0.54 | ★ 0.55 |
| Revenue | ★ $1,054,132,000.00 | $868,453,000.00 |
| Revenue This Year | $1.20 | $19.75 |
| Revenue Next Year | N/A | $12.88 |
| P/E Ratio | $111.61 | ★ $55.13 |
| Revenue Growth | 7.29 | ★ 21.51 |
| 52 Week Low | $41.15 | $25.52 |
| 52 Week High | $73.00 | $40.87 |
| Indicator | AIN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 55.43 |
| Support Level | $53.47 | $28.26 |
| Resistance Level | $60.14 | $33.11 |
| Average True Range (ATR) | 1.99 | 1.13 |
| MACD | -0.16 | -0.16 |
| Stochastic Oscillator | 45.77 | 60.99 |
Albany International Corp is a textiles and materials processing company specializing in engineered fabrics and composite components and assemblies for the paper, industrial manufacturing and aerospace industries. It operates through two segments: Machine Clothing, which produces custom-designed fabrics and high-speed process belts for paper, paperboard, tissue, towel and pulp, as well as engineered fabrics for other industrial applications, and contributes the majority of revenue; and Albany Engineered Composites, which provides engineered composite parts for the aerospace and defense industries. The company generates revenue from the United States, Switzerland, Brazil, China, Mexico, France and other areas.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.